ARICEPT ODT
LOE ApproachingNDAORALTABLET, ORALLY DISINTEGRATING
Approved
Oct 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ARICEPT ODT by Eisai is alzheimer’s disease attribute some of them to a deficiency of cholinergic neurotransmission. Approved for dementia of the alzheimer’s type. First approved in 2004.
Drug data last refreshed Yesterday
Mechanism of Action
Alzheimer’s disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition…
Indications (1)
Company
Worked on ARICEPT ODT at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.